`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`MYLAN PHARMACEUTICALS INC.,
`
`Petitioner,
`
`RESEARCH CORPORATION TECHNOLOGIES, INC.,
`Patent Owner.
`
`Case No. IPRZOI6-01248
`
`Patent No. RE 38,551
`
`PATENT OWNER’S UPDATED MANDATORY NOTICES
`
`UNDER 37 C.F.R. § 42.8
`
`
`
`Patent No. RE 38,551
`
`1
`
`Case No. IPR2016-01248
`
`Pursuant
`
`to 37 C.F.R.
`
`§ 42.8, Patent Owner Research Corporation
`
`Technologies, Inc. submits the following Updated Mandatory Notices to provide
`
`an update regarding related matters involving RE 38,551. All other information
`
`remains unchanged.
`
`A.
`
`Related Matters Under 37 C.F.R. § 42.8(b)(2)
`
`The related judicial proceedings involving RE 38,551 are shown below. On
`
`August 12, 2016, an Order issued in 1:13—cv-0l206—LPS (consolidated) (EX. 2004),
`
`intending to enter final judgment
`
`for the plaintiffs/patent owner against
`
`the
`
`defendants consistent with the Memorandum Opinion unsealed on August 15, 2016
`
`(Ex. 2003). See, e.g., Ex. 2003 at 86—91.
`
` Case Ca tion as - 3
`g
`,
`.
`I
`Disposition .
`UCB, Inc. et al. v. Teva Pharmaceuticals USA Inc.
`closed
`et al., 1:l3—cv—01148-LPS (D. Del.)
`UCB, Inc. et al. V. Accord Healthcare Inc. et al.,
`1:13—cv-0l206—LPS (D. Del.)
`UCB, Inc. et al. v. Alembic P/iarmaceuticals Ltd,
`1:13-cv—0l207—LPS (D. Del.)
`UCB, Inc. et al. v. Amneal Pharmaceuticals, LLC
`et al., 1:13-cv-0l208—LPS (D. Del.)
`UCB, Inc. et al. v. Apotex Corp. et al., 1:13-cv—
`0l209—LPS (D. Del.)
`UCB, Inc. et al. v. Aurobindo Pharma Ltd. et al.,
`1:13-cv—01210—LPS (D. Del.)
`UCB, Inc. et al. v. Breckenridge Plzarmaceutical
`Inc. etal., 1:l3—cv—01211-LPS (D. Del.)
`UCB, Inc. et al. v. Glenmark Generics Inc. USA et
`al., 1:13-cv—012l2—LPS (D. Del.)
`UCB, Inc. et al. v. Hetero USA Inc. et al., 1:13-cv— closed
`0l2l3—LPS (D. Del.)
`
`
`
`pending
`
`pending, consolidated with
`1:13—cv-0l206—LPS (D. Del
`pending, consolidated with
`1:13—cv-0l206—LPS (D. Del.)
`pending, consolidated with
`1:13—cv-0l206—LPS (D. Del.)
`pending, consolidated with
`#1:13—cv—0l206—LPS (D. Del.L
`pending, consolidated with
`1:13—cv-0l206—LPS (D. Del.)
`closed
`
`
`
`Patent No. RE 38,551
`
`Case No. IPR20l6—Ol248
`
`
`.
`Case Caption
`L
`i
`i
`.
`UCB, Inc. et al. v. Mylan Pharmaceuticals Inc. et
`al., l:l3—cV-0l214—LPS (D. Del.)
`UCB, Inc. et al. v. Ranbaxy Laboratories Ltd. et
`al., 1:13-cV—Ol2l5—LPS (D. Del.)
`UCB, Inc. etal. v. Sandoz Inc., l:l3—cv—Ol216-
`LPS (D. Del.)
`UCB, Inc. et al. v ScieGen Pharmaceuticals Inc. et
`
`
`I
`I
`Qgposition
`pending, consolidated with
`1:13-cv—()l206—LPS (D. Del.)
`closed
`
`closed
`
`closed
`
`al., 1:13-CV-01217-LPS (D. Del.)
`UCB, Inc. et al. v Sun Pharma Global FZE et al.,
`1: l3-cV—O12l8—LPS (D. Del.)
`UCB, Inc. et al. v. Watson Laboratories Inc. —
`
`Florida et al., l:13—cV-0l219—LPS (D. Del.)
`UCB, Inc. et al. v. Zydus Pharmaceuticals (USA)
`Inc. et al., 1:13-cv-01220-LPS (D. Del.)
`UCB, Inc. et al. v. Apotex Corp. et al., 1:14-cv-
`00834—LPS (D. Del.)
`UCB, Inc. et al. v. Sun Pharma Global FZE et al.,
`1:13-CV-05514 (ND. 111.)
`UCB, Inc. et al. v. Zydus Pharmaceuticals (USA),
`Inc. et al., 3:13-CV-04021 (D.N.J.)
`UCB, Inc. et al. v. Aurobindo Pharma Ltd. et al.,
`1:16—cV—00451 (D. Del.)
`UCB, Inc. et al. v. Hetero USA Inc. et al., 1:l6-cV-
`00452 D. Del.)
`
`
`
`pending, Consolidated with
`1:13—cV—012O6-LPS (D. Del.)
`pending, consolidated with
`1:13-cV—01206—LPS (D. Del.)
`pending, consolidated with
`1:13-cv-O1206—LPS (D. Del.)
`pending, consolidated with
`1:l3—cV—O1206—LPS (D. Del.)
`closed
`
`closed
`
`pending
`
`pending
`
`
`
`Patent No. RE 38,551
`
`Case No. IPR2016-01248
`
`Date: August 19, 2016
`
`Respectfully submitted,
`
`By
`
`,%ZZ
`
`drea G. Reister
`
`Registration No. 36,253
`Jennifer L. Robbins
`
`Registration No. 61,163
`COVINGTON & BURLING LLP
`
`One CityCenter, 850 Tenth Street, NW
`Washington, DC 20001
`(202) 662-6000
`Attorneys for Patent Owner
`
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. § 42.6, I hereby certify that on this 19th day of August
`
`2016,
`
`the foregoing Patent Owner’s Updated Mandatory Notices Under 37
`
`C.F.R. § 42.8 was served by electronic mail, by agreement of the parties, on the
`
`following counsel of record for Petitioner.
`
`Steven W. Parmelee (sparrne1ee@wsgr.com)
`Michael T. Rosato (mrosato@wsgr.corn)
`Jad A. Mills (jn1ills@wsgr.corn)
`Wilson Sonsini Goodrich & Rosati
`
`701 Fifth Avenue, Suite 5100
`Seattle, WA 98104-7036
`
`Date: August 19, 2016
`
`
`
`ennifer L. Robbins, Esq.
`Registration No.: 61,163